“We may not be able to demonstrate sufficient efficacy or safety of our COVID-19 vaccine and/or variant-specific formulations to obtain permanent regulatory approval in the United States, the United Kingdom, the European Union, or other countries where it has been authorized for emergency use or granted conditional marketing approval. Significant adverse events may occur during our clinical trials or even after receiving regulatory approval, which could delay or terminate clinical trials, delay or prevent regulatory approval or market acceptance of any of our product candidates.”
BioNTech
BioNTech is a German biotechnology company specializing in the development of immunotherapies, particularly mRNA-based vaccines.
This statement demonstrates the scientific honesty and transparency of a company that, despite success and recognition, warns of potential risks and obstacles.
Translation or original: 🇩🇪Click here
Quelle: Hier klicken
i
BioNTech Quote on COVID-19 Vaccine Safety and Efficacy – Honesty and Risks Explained
BioNTech warns that permanent approval of its COVID-19 vaccine depends on efficacy and safety, with risks during clinical trials.
BioNTech SE was founded in 2008 in Mainz, Germany, and gained worldwide recognition for developing one of the first approved mRNA-based COVID-19 vaccines in collaboration with Pfizer. The company researches personalized cancer vaccines and other immunotherapeutic approaches.
Leave a Reply
Want to join the discussion?Feel free to contribute!